TrialSignal
Clinical trial intelligence report
Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy: a Randomized, Non-comparative, Placebo-controlled, Single-blinded, Phase II Clinical Trial in Cancer Patients
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT06834685-Jul 28, 2026
NCT ID
NCT06834685
Status
RECRUITING
Phase
NA
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Executive brief
Investment-Ready Snapshot
Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy: a Randomized, Non-comparative, Placebo-controlled, Single-blinded, Phase II Clinical Trial in Cancer Patients is a NA clinical asset sponsored by Institut du Cancer de Montpellier
Val d'Aurelle in Cancer Survivors, Peripheral Neuropathic Pain. SEO and diligence focus: Photobiomodulation sessions, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06834685
Indication
Cancer Survivors
Modality
medical device
Target
Photobiomodulation sessions
Intervention
Photobiomodulation sessions
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.